六分区活检定义的优势前列腺内病灶推量对永久性碘-125前列腺植入生化无病生存与毒性的影响
该回顾性研究纳入2005至2013年165例中危前列腺癌患者,均接受碘-125低剂量率近距离治疗,前列腺剂量144 Gy,其中55例根据六分区活检图对优势前列腺内病灶(DIL)进行推量至150%等剂量线覆盖。中位随访78个月,DIL组7年生化无病生存(bDFS)为96%,对照组为89%(p=0.188),两组泌尿、胃肠及性毒性至5年随访无差异。
要点
- DIL推量组7年bDFS为96%,对照组89%,差异无统计学意义(p=0.188)。
- 两组至5年随访的泌尿、胃肠及性毒性无差异。
- DIL组仅1例≥3级毒性(经尿道前列腺电切术),对照组无。
核心结论
- 基于六分区活检定义的DIL推量在永久性前列腺植入中显示中危前列腺癌生化控制改善趋势,且未增加毒性。
研究设计与样本
- 回顾性研究,纳入2005年1月至2013年12月165例中危前列腺癌患者,均接受碘-125低剂量率近距离治疗,前列腺剂量144 Gy,其中55例接受DIL推量。
主要发现
- 中位随访78个月,DIL组7年bDFS为96%(95% CI 74-99%),对照组为89%(95% CI 79-94%),p=0.188。
- 至5年随访,两组泌尿、胃肠及性毒性无差异。
- DIL组仅1例≥3级毒性(经尿道前列腺电切术),对照组无。
关键数值与推荐
- DIL由六分区活检定义,规划前前瞻性勾画,需被150%等剂量线覆盖。
- bDFS依据Phoenix共识定义判定。
- 胃肠毒性依据CTCAE v4.03分级。
- 勃起功能障碍定义为无法达到足以完成性交的勃起。
临床怎么用
- 中危前列腺癌患者行碘-125永久植入时,可基于六分区活检图对DIL推量至150%等剂量线,未增加毒性。
- DIL推量对生化控制的改善仅为趋势,需进一步验证。
局限性
- 回顾性研究设计,DIL组样本量较小(55例),bDFS差异未达统计学显著性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: To compare bDFS and toxicity outcomes in a population of intermediate risk prostate cancer patients treated using I-125 LDR brachytherapy with or without DIL boost based on multiple core biopsy maps. MATERIALS AND METHODS: Between January 2005 and December 2013, all our intermediate risk prostate cancer patients treated with LDR I-125 brachytherapy were reviewed. All patients were given 144 Gy to the prostate. A pathologic DIL distribution (defined by sextant biopsy) was contoured prospectively prior to planning, to be covered by the 150% isodose line. Of the 165 patients treated, 55 received a DIL boost. Patients completed prospectively the IPSS questionnaire, a sexual and bowel function questionnaire. Gastro-intestinal toxicities were graded according to CTCAE v4.03. A patient was considered to have erectile dysfunction if he was unable to achieve erection to perform intercourse. BDFS was determined according to the Phoenix consensus definitions. RESULTS: The median follow-up was 78 months. The estimated 7-year bDFS rate was 96% (95% CI, 74-99%) in the DIL group versus 89% (95% CI, 79-94%) in the control group (p = 0.188). There was no difference between groups in urinary, gastro-intestinal or sexual toxicities up to 5 years of follow-up. There was no difference in urinary obstruction with catheterization between DIL versus control groups (3,6 vs 2,8 %, p = 1.00). Only 1 patient in the DIL group had ≥grade 3 toxicity (TURP) and none in the control group. CONCLUSIONS: Boost to DIL defined by sextant biopsy with permanent seed prostate implant shows a trend toward improvement of biochemical control in intermediate risk prostate cancer patient without increasing toxicity.
引用
- Guimond E, Lavallée MC, Foster W, et al. Impact of a dominant intraprostatic lesion (DIL) boost defined by sextant biopsy in permanent I-125 prostate implants on biochemical disease free survival (bDFS) and toxicity outcomes. Radiother Oncol. 2019. PMID: 30935583. doi:10.1016/j.radonc.2018.12.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。